{
  "id": 19793039,
  "title": "Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028",
  "url": "https://urgent.news/2026/11/13/prediction-10-000-invested-in-viking-therapeutics-before-its-oral-19793039",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-13T09:35:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/prediction-10000-invested-viking-therapeutics-its-oral-phase-3-readouts-could-be-worth"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsViking's oral phase 3 obesity trial is key to expanding its addressable market and securing a favorable market share.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}